Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SAGE)

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Business Wire 3 days ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Business Wire October 29, 2024

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE

Accesswire October 28, 2024

Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc. (SAGE)

Accesswire October 28, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics

Newsfile October 28, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE

Accesswire October 28, 2024

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

PR Newswire October 28, 2024

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire October 28, 2024

Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire October 28, 2024
View More News ››

Opinion & Analysis (NDAQ:SAGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SAGE)

Sage Therapeutics Announces Topline Results from the Phase 2

NEWS: $SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of...
whytestocks - 2 days ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gew

BREAKING NEWS: $SAGE Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek...
whytestocks - July 25, 2024

Neurodegenerative Disorder-Focused Sage Therapeutics Stock F

JUST IN: $SAGE Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data...
whytestocks - April 17, 2024

Neutral Recommendation Issued On SAGE By Goldman Sachs

BREAKING NEWS: $SAGE Neutral Recommendation Issued On SAGE By Goldman Sachs2024-04-17 12:30:03 ET Goldman Sachs analyst issues NEUTRAL...
whytestocks - April 17, 2024

SAGE Price Target Alert: $22.00. Issued by Truist Financial

BREAKING NEWS: $SAGE SAGE Price Target Alert: $22.00. Issued by Truist Financial2024-04-17 12:00:02 ET Joon Lee from Truist Financial...
whytestocks - April 17, 2024

Market Perform Recommendation Issued On SAGE By Raymond Jame

BREAKING NEWS: $SAGE Market Perform Recommendation Issued On SAGE By Raymond James2024-04-17 11:30:02 ET Raymond James analyst issues...
whytestocks - April 17, 2024
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »